Multicenter study for CH-VAD as a fully magnetically levitated left ventricular assist device.

Area of Science:

• Cardiology
• Biomedical Engineering
• Medical Devices

Background:

• End-stage heart failure (HF) necessitates advanced mechanical circulatory support.
• Left ventricular assist devices (LVADs) are crucial for managing advanced HF.
• Optimizing hemocompatibility and device reliability is paramount for LVADs.

Purpose of the Study:

• To evaluate the clinical outcomes of the CH-VAD, a magnetically levitated LVAD.
• To assess the safety and efficacy of the CH-VAD in Chinese patients with end-stage HF.
• To compare CH-VAD performance against international LVAD benchmarks.

Main Methods:

• A prospective study involving 77 patients implanted with the CH-VAD across seven Chinese centers.
• Data collection from June 2022 to June 2024, including patient demographics, HF etiology, and INTERMACS profiles.
• Monitoring of survival rates, adverse events (e.g., right heart failure, bleeding, infection), pump thrombosis, and device failure.

Main Results:

• A 91.6% survival rate was observed at both 6-month and 1-year follow-ups.
• Low incidence of key adverse events, including right heart failure, reoperation for bleeding, and driveline infections.
• No instances of pump thrombosis or device failure were reported during the study period.

Conclusions:

• The CH-VAD demonstrates excellent short-to-mid-term clinical outcomes in Chinese patients with end-stage HF.
• The device exhibits favorable hemocompatibility and reliability, comparable to international standards.
• The CH-VAD represents a viable and effective long-term mechanical circulatory support solution, meriting further long-term efficacy studies.